Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Trevi Therapeutics (NASDAQ: TRVI) announced participation in several investor events in May 2023. The events include the Aegis Virtual Conference from May 2-4, where senior management will present on May 3, and the American Thoracic Society's Respiratory Innovation Summit from May 19-20, with a presentation on May 20. Additionally, Trevi will be featured at the Yale Innovation Summit from May 31 to June 1. The focus of Trevi Therapeutics is on Haduvio™, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and other conditions. Haduvio aims to provide a novel treatment through an oral formulation of nalbuphine. Trevi's leadership, including President and CEO Jennifer Good, will address investors at these key events.